Aktienanalyse zu Inventiva SA (IVA)IVAInventiva SA

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology. It operates in the Healthcare sector.

Inventiva SA (IVA) presents a compelling buying opportunity at the current price of $4.705, especially considering the upcoming Phase 3 trial results for lanifibranor, expected in Q4 2026. The stock has shown a 5.02% increase over the last 20 days, indicating positive momentum. Moreover, hedge funds have increased their buying activity by 681.82% over the last quarter, suggesting strong institutional interest. However, the company reported no revenue for Q1 2026, which remains a significant risk to its financial stability.